Journal Watch · Frontiers in Immunology · 2026
CD4<sup>+</sup> and CD8<sup>+</sup> T cells contribute to psoriasis phenotype when integrated into human skin equivalents for drug testing.
Overall, our findings contribute to the refinement of human skin models for studying disease pathophysiology and evaluating therapeutic responses, enabling more accurate predictions of drug efficacy and safety.
TL;DR
Overall, our findings contribute to the refinement of human skin models for studying disease pathophysiology and evaluating therapeutic responses, enabling more accurate predictions of drug efficacy and safety.
Key findings
- Notably, the presence of CD8<sup>+</sup> T cells altered the efficacy of treatment with the psoriasis drug apremilast.
- Overall, our findings contribute to the refinement of human skin models for studying disease pathophysiology and evaluating therapeutic responses, enabling more accurate predictions of drug efficacy and safety.
What they did
Our aim was to establish a human experimental model incorporating different CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets into a human full-thickness skin equivalent (hFTSE) to investigate their individual and combined contribution to the pathogenesis of psoriasis. Across all conditions, migration of inserted T cells towards the epidermis and the secretion of psoriasis-associated cytokines (IFN-γ, IL-17, TNF-α, IL-1β, CCL20, IL-6, and IL-10) was observed. Immunohistological analysis revealed psoriasis-associated alteration of epidermal differentiation, as well as enhanced expression of keratinocyte-mediated antimicrobial peptides (AMPs) in T cell-incorporated hFTSEs.
Full abstract (original)
Background: The limited translational potential of experimental animal models for human skin disease pathophysiology demands the development of more suitable immunocompetent human experimental models. Psoriasis ranks among the most prevalent human inflammatory skin disorders, initiated and manifested by the interplay of T cells with epidermal keratinocytes. Current <i>in vitro</i> models recapitulate psoriasis-like pathology by incorporating CD4<sup>+</sup> T cell subsets into skin equivalents, but lack CD8<sup>+</sup> T cells, key mediators of epidermal inflammation and chronic disease.
What they did: Our aim was to establish a human experimental model incorporating different CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets into a human full-thickness skin equivalent (hFTSE) to investigate their individual and combined contribution to the pathogenesis of psoriasis. Across all conditions, migration of inserted T cells towards the epidermis and the secretion of psoriasis-associated cytokines (IFN-γ, IL-17, TNF-α, IL-1β, CCL20, IL-6, and IL-10) was observed. Immunohistological analysis revealed psoriasis-associated alteration of epidermal differentiation, as well as enhanced expression of keratinocyte-mediated antimicrobial peptides (AMPs) in T cell-incorporated hFTSEs.
Results & conclusions: Notably, the presence of CD8<sup>+</sup> T cells altered the efficacy of treatment with the psoriasis drug apremilast. Overall, our findings contribute to the refinement of human skin models for studying disease pathophysiology and evaluating therapeutic responses, enabling more accurate predictions of drug efficacy and safety.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1790531 · PubMed 42039187.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Overall, our findings contribute to the refinement of human skin models for studying disease pathophysiology and evaluating therapeutic responses, enabling more accurate predictions of drug efficacy and safety.
What type of study is this?
It is a in-vitro / cell study, published in Frontiers in Immunology in 2026. Our aim was to establish a human experimental model incorporating different CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets into a human full-thickness skin equivalent (hFTSE) to investigate their individual and combined contribution to the pathogenesis of psoriasis.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1790531. PubMed ID: 42039187. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd4-lt-sup-gt-lt-sup-gt-and-cd8-lt-sup-gt-lt-sup-gt-t-cells-contribute-t-790531/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides